The classification and treatment of antibody-mediated renal allograft injury: Where do we stand?
- 1 January 2007
- journal article
- editorial
- Published by Elsevier in Kidney International
- Vol. 71 (1), 7-11
- https://doi.org/10.1038/sj.ki.5002003
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetilKidney International, 2007
- The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantationTransplant International, 2006
- The emerging role of rituximab in organ transplantationTransplant International, 2006
- Acute and Chronic Vascular Rejection in Nonhuman Primate Kidney TransplantationAmerican Journal of Transplantation, 2006
- Nodular B-Cell Aggregates Associated with Treatment Refractory Renal Transplant Rejection Resolved by RituximabAmerican Journal of Transplantation, 2006
- Factors Associated With and Predictive of Persistence of Donor-Specific Antibody After Treatment With Plasmapheresis and Intravenous ImmunoglobulinHuman Immunology, 2005
- Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximabClinical Transplantation, 2004
- RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)Transplantation, 2003
- BK Virus Infection after Kidney TransplantationGraft, 2002
- POLYOMAVIRUS DISEASE UNDER NEW IMMUNOSUPPRESSIVE DRUGSTransplantation, 1999